IGM Biosciences to Present at Three Upcoming Investor Conferences

Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, has announced that CEO Fred Schwarzer will speak at three major investor conferences in New York. The conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, Baird 2022 Global Healthcare Conference on September 13, and H.C. Wainwright 24th Annual Global Investment Conference on September 14. Live webcasts will be available on the company's website, with replays archived for 90 days.

MOUNTAIN VIEW, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in three upcoming investor conferences in New York:

• Fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12 at 1:40 p.m. EST
• Fireside chat at the Baird 2022 Global Healthcare Conference on Tuesday, September 13 at 3:45 p.m. EST
• H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 3:30 p.m. EST
  

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.

About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

What conferences will IGM Biosciences participate in September 2022?

IGM Biosciences will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, the Baird 2022 Global Healthcare Conference on September 13, and the H.C. Wainwright 24th Annual Global Investment Conference on September 14.

Who will represent IGM Biosciences at the investor conferences?

Fred Schwarzer, the Chief Executive Officer of IGM Biosciences, will represent the company at all three investor conferences.

Where can I watch the IGM Biosciences conference presentations?

Live webcasts of the presentations can be accessed on the 'Events and Presentations' page of IGM Biosciences' website.

What is the focus of IGM Biosciences?

IGM Biosciences focuses on developing IgM antibodies to treat cancer, infectious diseases, and autoimmune diseases.

How long will the webcasts from IGM Biosciences be available?

The replays of the webcasts will be archived on IGM Biosciences' website for 90 days following the presentations.